Roth Capital analyst Debjit Chattopadhyay was out pounding the table on bluebird bio Inc (NASDAQ:BLUE) Monday, reiterating a Buy rating and price target …
Roth Capital analyst Debjit Chattopadhyay weighed in today with a favorable report on Sarepta Therapeutics Inc (NASDAQ:SRPT), after the company announced the completion of its …
Vical Incorporated (NASDAQ:VICL) shares are tumbling 42.85% to $0.
Roth Capital analyst Debjit Chattopadhyay was out pounding the table on Nektar Therapeutics (NASDAQ:NKTR) Thursday, maintaining a Buy rating on the stock with …
Roth Capital analyst Debjit Chattopadhyay weighed in with a few of his opinions on CTI BioPharma Corp (NASDAQ:CTIC) after the company released new patient-reported outcome (PRO) …
Roth Capital analyst Debjit Chattopadhyay was out pounding the table on Uniqure NV (NASDAQ:QURE) Friday, reiterating a Buy rating and price target of $38 …
Roth Capital analyst Debjit Chattopadhyay came out with a research note on Vical Incorporated (NASDAQ:VICL), as the company is expected to release top-line …
In a research report released Sunday, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics Inc. (NASDAQ:SRPT) with a price …
In a research report released today, Roth Capital analyst Debjit Chattopadhyay initiated coverage on shares of Vical Incorporated (NASDAQ:VICL) with a Buy rating and a $4.65 …
Roth Capital analyst Debjit Chattopadhyay was out pounding the table on CTI BioPharma Corp. (NASDAQ:CTIC), reiterating a Buy rating and price target of $4.
